TolerMab TRX 4 - TolerRx

Drug Profile

TolerMab TRX 4 - TolerRx

Alternative Names: TolerMab anti-CD3 monoclonal antibody - TolerRx; TolerMab TRX4; TRX 4 - TolerMab - TolerRx

Latest Information Update: 01 Sep 2005

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TolerRx
  • Class Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Type 1 diabetes mellitus

Most Recent Events

  • 01 Sep 2005 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
  • 01 Sep 2005 Discontinued - Preclinical for Type-1-diabetes-mellitus in USA (unspecified route)
  • 05 Jul 2003 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top